立体定向消融放疗治疗寡转移性乳腺癌的系统综述与荟萃分析
SABR实现持久局部控制且≥3级不良事件仅1.50%,新发寡转移(OM)患者的局部控制、无进展生存、总生存及至下次系统治疗时间均优于寡进展(OP)患者;4项随机试验汇总PFS风险比为0.73(95%CI 0.53-1.00;P=0.053),既未证实也未排除获益。
要点
- SABR在寡转移性乳腺癌中1年局部控制92.5%、2年84.6%,≥3级不良事件1.50%。
- 新发OM较OP的2年LC、PFS、OS及TTNS均更优,临床情境决定系统获益。
- 4项随机试验汇总PFS HR 0.73(0.53-1.00;P=0.053),证据不确定。
核心结论
- SABR在各临床情境下均实现持久局部控制且治疗相关不良事件少。
- 临床情境而非剂量或转移部位决定局部效应能否转化为系统获益。
- 随机证据既未证实也未排除获益,需按寡转移状态分层的试验。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、Cochrane CENTRAL和ClinicalTrials.gov至2026年3月。
- 采用随机效应模型汇总比例,不良事件用二项-正态模型并单独汇总随机试验。
主要发现
- 1年局部控制92.5%(95%CI 90.4-94.2),2年84.6%(81.1-87.6),与BED10无关联。
- 2年无进展生存43.1%(34.4-52.2),总生存85.8%(76.0-92.0)。
- 新发OM较OP:LC 95.7%对88.9%(P=0.001),PFS 50.9%对30.9%(P=0.003),OS 91.0%对65.8%(P=0.002)。
- 新发OM较OP的至下次系统治疗时间为18.5对11.3个月。
- OP中病灶数与TTNS独立相关(校正HR 1.77/病灶)。
关键数值与推荐
- 4项随机试验汇总PFS风险比0.73(95%CI 0.53-1.00;P=0.053)。
- ≥3级不良事件21/1366例(1.50%;95%CI 0.74-2.28)。
临床怎么用
- SABR可用于寡转移性乳腺癌,局部控制持久且严重不良事件发生率低。
- 新发OM患者较OP患者更可能从SABR获得系统获益,OP患者需综合评估。
- OP患者病灶数目增多与至下次系统治疗时间缩短相关,应个体化决策。
局限性
- 随机证据有限且汇总PFS未达统计学显著(P=0.053),获益不确定。
- 队列研究异质性可能影响汇总结果,需按寡转移状态分层的随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Stereotactic ablative radiotherapy (SABR) is increasingly used for oligometastatic breast cancer, but it is unclear in whom local ablation translates into systemic benefit. We compared de novo oligometastatic (OM) with oligoprogressive (OP) disease and synthesised randomised evidence. MATERIALS AND METHODS: PubMed, EMBASE, Cochrane CENTRAL and ClinicalTrials.gov were searched through March 2026. Endpoints were local control (LC), progression-free survival (PFS), overall survival (OS), time to next systemic therapy (TTNS) and grade 3 or higher adverse events. Proportions were pooled by random-effects models, adverse events by a binomial-normal model accommodating zero-event studies, and trials separately. RESULTS: Twenty-five cohorts (1,577 patients; 2,211 lesions) were included. Pooled LC was 92.5 % (95 % CI 90.4-94.2) at one year and 84.6 % (81.1-87.6) at two years, with no association with BED10. At two years, PFS was 43.1 % (34.4-52.2) and OS 85.8 % (76.0-92.0). Outcomes were consistently superior in de novo OM than in OP: LC 95.7 % versus 88.9 % (p = 0.001), PFS 50.9 % versus 30.9 % (p = 0.003), OS 91.0 % versus 65.8 % (p = 0.002), and TTNS 18.5 versus 11.3 months. Within OP, lesion number was independently associated with TTNS (adjusted HR 1.77 per lesion). Across four randomised trials the pooled hazard ratio for PFS was 0.73 (0.53-1.00; p = 0.053). Grade 3 or higher adverse events occurred in 21 of 1,366 patients (1.50 %; 0.74-2.28). CONCLUSIONS: SABR achieves durable local control with few treatment-related adverse events in all clinical contexts. Clinical context, rather than dose or metastatic site, determines whether that local effect translates into systemic benefit. Randomised evidence neither establishes nor excludes a benefit; trials stratified by oligometastatic state are required.
引用
- Viani GA, Hamamura AC, Arruda CV, et al. Stereotactic ablative radiotherapy for oligometastatic breast cancer: A systematic review and meta-analysis (SABRINA). Radiother Oncol. 2026. PMID: 42764105. doi:10.1016/j.radonc.2026.111789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。